HTG Molecular Diagnostics, Inc. (HTGMQ) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Diagnostics & Research 산업에서 운영. 본사 소재지는 Tucson, AZ, 미국. 현재 CEO는 John L. Lubniewski.
HTGMQ 을(를) 보유 IPO 날짜 2015-05-06, 53 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $221.00.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
